BlackRock Institutional Trust’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BlackRock Institutional Trust’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.67M	Sell	352,282 -12,002	-3%	-$65.3K	﹤0.01%	3125
2016 Q3	$2.41M	Buy	364,284 +6,216	+2%	+$33.1K	﹤0.01%	2977
2016 Q2	$1.96M	Sell	358,068 -14	-0%	-$223	﹤0.01%	3050
2016 Q1	$7.66M	Buy	358,082 +19,312	+6%	+$432K	﹤0.01%	2443
2015 Q4	$10.7M	Buy	338,770 +17,810	+6%	+$629K	﹤0.01%	2280
2015 Q3	$11M	Buy	320,960 +237,388	+284%	+$7.18M	﹤0.01%	2231
2015 Q2	$2.63M	Buy	83,572 +11,952	+17%	+$352K	﹤0.01%	3009
2015 Q1	$2.1M	Buy	71,620 +15,232	+27%	+$357K	﹤0.01%	3093
2014 Q4	$1.04M	Sell	56,388 -1,572	-3%	-$26.5K	﹤0.01%	3342
2014 Q3	$1.01M	Sell	57,960 -2,604	-4%	-$48.6K	﹤0.01%	3321
2014 Q2	$1.21M	Buy	60,564 +58,340	+2,623%	+$1.13M	﹤0.01%	3383
2014 Q1	$42K	Buy	+2,224	New	+$46.2K	﹤0.01%	3833

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock Institutional Trust's MRTX Position: Q4 2016 in Review

BlackRock Institutional Trust reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 3.3% in Q4 2016, selling an estimated $65.3K and leaving 352,282 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3125.

BlackRock Institutional Trust first reported a position in MRTX in Q1 2014 and has held it in 12 quarters since. The position peaked at $11M in Q3 2015. 62 funds tracked by Wall St. Rank hold MRTX as of Q4 2016.

BlackRock Institutional Trust held 352,282 shares of Mirati Therapeutics, Inc. Common Stock worth $1.67M as of Q4 2016.
BlackRock Institutional Trust sold 12,002 Mirati Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $65.3K.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3125 holding.
BlackRock Institutional Trust first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Mirati Therapeutics, Inc. Common Stock position peaked at $11M in Q3 2015.
62 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.